ALAFY Fundamental Analysis - AFYREN SAS

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALAFY. ALAFY was compared to 66 industry peers in the Chemicals industry. The financial health of ALAFY is average, but there are quite some concerns on its profitability. ALAFY has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALAFY had negative earnings in the past year.

In the past year ALAFY has reported a negative cash flow from operations.

In the past 5 years ALAFY always reported negative net income.

In the past 5 years ALAFY always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -16.66%, ALAFY is doing worse than 83.33% of the companies in the same industry.

The Return On Equity of ALAFY (-18.51%) is worse than 78.79% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.66%
ROE	-18.51%
ROIC	N/A

ROA(3y)-13.7%

ROA(5y)-10.19%

ROE(3y)-15.66%

ROE(5y)-12.5%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 88.40%, ALAFY belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

In the last couple of years the Gross Margin of ALAFY has declined.

ALAFY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	88.4%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.47%

GM growth 5Y-1.95%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALAFY does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALAFY has been increased compared to 1 year ago.

Compared to 5 years ago, ALAFY has more shares outstanding

Compared to 1 year ago, ALAFY has an improved debt to assets ratio.

2.2 Solvency

ALAFY has an Altman-Z score of 6.65. This indicates that ALAFY is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 6.65, ALAFY belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.

A Debt/Equity ratio of 0.04 indicates that ALAFY is not too dependend on debt financing.

ALAFY has a Debt to Equity ratio of 0.04. This is amongst the best in the industry. ALAFY outperforms 93.94% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF	N/A
Altman-Z	6.65

ROIC/WACCN/A

WACC7.55%

2.3 Liquidity

ALAFY has a Current Ratio of 15.87. This indicates that ALAFY is financially healthy and has no problem in meeting its short term obligations.

ALAFY has a Current ratio of 15.87. This is amongst the best in the industry. ALAFY outperforms 100.00% of its industry peers.

ALAFY has a Quick Ratio of 15.87. This indicates that ALAFY is financially healthy and has no problem in meeting its short term obligations.

ALAFY's Quick ratio of 15.87 is amongst the best of the industry. ALAFY outperforms 100.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.87
Quick Ratio	15.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALAFY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.24%.

ALAFY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.30%.

Measured over the past years, ALAFY shows a small growth in Revenue. The Revenue has been growing by 4.31% on average per year.

EPS 1Y (TTM)-1.24%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1.05%

Revenue 1Y (TTM)-15.3%

Revenue growth 3Y-1.95%

Revenue growth 5Y4.31%

Sales Q2Q%5.27%

3.2 Future

The Earnings Per Share is expected to grow by 6.59% on average over the next years.

The Revenue is expected to grow by 0.48% on average over the next years.

EPS Next Y-12.22%

EPS Next 2Y1.11%

EPS Next 3Y6.59%

EPS Next 5YN/A

Revenue Next Year-5.8%

Revenue Next 2Y-2.94%

Revenue Next 3Y0.48%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALAFY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALAFY. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y1.11%

EPS Next 3Y6.59%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALAFY!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AFYREN SAS

EPA:ALAFY (9/19/2025, 7:00:00 PM)

2.57

0 (0%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners12.35%

Inst Owner ChangeN/A

Ins Owners10.68%

Ins Owner ChangeN/A

Market Cap67.10M

Analysts86

Price Target5.3 (106.23%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)4%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-40.28%

EPS NY rev (3m)-40.28%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-26.13%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	23.45
P/FCF	N/A
P/OCF	N/A
P/B	1.27
P/tB	1.35
EV/EBITDA	N/A

EPS(TTM)-0.37

EYN/A

EPS(NY)-0.52

Fwd EYN/A

FCF(TTM)-0.22

FCFYN/A

OCF(TTM)-0.22

OCFYN/A

SpS0.11

BVpS2.02

TBVpS1.91

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.66%
ROE	-18.51%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	88.4%
FCFM	N/A

ROA(3y)-13.7%

ROA(5y)-10.19%

ROE(3y)-15.66%

ROE(5y)-12.5%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.47%

GM growth 5Y-1.95%

F-Score4

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	25.97%
Cap/Sales	7.72%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	15.87
Quick Ratio	15.87
Altman-Z	6.65

F-Score4

WACC7.55%

ROIC/WACCN/A

Cap/Depr(3y)59.69%

Cap/Depr(5y)64.66%

Cap/Sales(3y)13.21%

Cap/Sales(5y)12.63%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-1.24%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1.05%

EPS Next Y-12.22%

EPS Next 2Y1.11%

EPS Next 3Y6.59%

EPS Next 5YN/A

Revenue 1Y (TTM)-15.3%

Revenue growth 3Y-1.95%

Revenue growth 5Y4.31%

Sales Q2Q%5.27%

Revenue Next Year-5.8%

Revenue Next 2Y-2.94%

Revenue Next 3Y0.48%

Revenue Next 5YN/A

EBIT growth 1Y-2.53%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year45.95%

EBIT Next 3Y22.09%

EBIT Next 5YN/A

FCF growth 1Y-4.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-11.55%

OCF growth 3YN/A

OCF growth 5YN/A

AFYREN SAS (ALAFY.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens